Back to mobile site

BMO Capital Starts C4 Therapeutics (CCCC) at Outperform

October 27, 2020 4:33 AM EDT Send to a Friend
BMO Capital analyst George Farmer initiates coverage on C4 Therapeutics (NASDAQ: CCCC) with a Outperform rating and a price target ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login